



April 1, 2020

**SIMPONI[®] self-injection formulation
for ulcerative colitis now reimbursed through NHI**

Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka; President & Representative Director: Hiroaki Ueno) announced today that the SIMPONI[®] subcutaneous injection 50 mg syringe (hereafter, SIMPONI) and the SIMPONI[®] subcutaneous injection 50 mg autoinjector (hereafter, SIMPONI Autoinjector) are now reimbursed through National Health Insurance (NHI) as a self-injection formulation for treatment of adults with moderate to severe ulcerative colitis (UC). Mitsubishi Tanabe Pharma has a co-promotion agreement with Janssen Pharmaceutical K.K. for the SIMPONI and SIMPONI Autoinjector in Japan. Under the terms of this agreement, promotion of SIMPONI and SIMPONI Autoinjector to healthcare professionals in Japan is undertaken by both companies.

In Japan, SIMPONI was approved for the treatment of rheumatoid arthritis (RA) in patients for whom other existing treatments have failed (including those who have structural joint damage) in July 2011, and for the treatment of moderate to severe UC in patients for whom other existing treatments have failed, in March 2017. In April 2018, SIMPONI was reimbursed through NHI as a self-injection formulation for the treatment of RA. In March 2019, the SIMPONI Autoinjector was approved by the Ministry for Health, Labor and Welfare (MHLW) for all approved indications in Japan.

This reimbursement extends the range of treatment choices for those living with UC, who now have the option to self-inject at home instead of taking regular and time-consuming trips to their physician.

Going forward, in the field of inflammatory bowel disease (Crohn's disease, ulcerative colitis), Mitsubishi Tanabe Pharma will offer REMICADE[®] and STELARA[®] for the indication of Crohn's disease and REMICADE[®] and SIMPONI[®] and STELARA[®] for the indication of ulcerative colitis. In this way, Mitsubishi Tanabe Pharma will strive to strategically reinforce its foundation in the field of inflammatory bowel

disease and contribute to improvements in patients' quality of life and to their medical treatment.

Mitsubishi Tanabe Pharma Corporation
Corporate Communications Department
Media contacts: TEL:+81 6 6205 5119